gearinjectuk.com
No products in the cart.
Return To Shopgearinjectuk.com
No products in the cart.
Return To ShopFor athletes and individuals managing diabetes, having reliable access to insulin is crucial. The Apidra Solostar Ready Pen by Sanofi provides a convenient and effective solution. Purchasing this product here ensures not only competitive pricing but also a commitment to quality and customer service. This ready pen is pre-filled, easy to use, and features a dial that allows for precise dosing, making it an essential tool for anyone on insulin therapy. Additionally, buying from a reputable source guarantees the integrity of the product, so you can focus on your performance rather than your medication.
Apidra Solostar is an insulin glulisine formulation designed to provide rapid-acting insulin therapy for individuals with diabetes. As a fast-acting insulin, it begins to work quickly after injection, usually within 15 minutes, and peaks between 30 to 90 minutes. The pen itself contains 3 mL of insulin glulisine, which is a modified form of human insulin designed to mimic the body’s natural insulin response after meals. The composition also includes excipients such as glycerol, metacresol, and water for injection, which contribute to its stability and effectiveness. The activity of Apidra demonstrates a swift decline in glucose levels post-meal, promoting optimal glycemic control for those engaged in athletic activities.
Insulin glulisine, the active ingredient in Apidra, operates by binding to insulin receptors on cells, facilitating the uptake of glucose from the bloodstream. This action enhances cellular glucose metabolism, providing energy for muscle contraction and recovery during and after physical activity. Moreover, it inhibits hepatic glucose production, contributing to better management of blood sugar levels. The rapid onset and short duration of action make Apidra particularly beneficial for athletes who require quick regulation of their blood glucose, optimizing energy availability during performance.
Numerous studies highlight the positive impact of insulin therapy on athletic performance. Apidra has been shown to enhance performance outcomes by providing a stable source of energy. Athletes using Apidra report improved endurance and reduced fatigue during workouts. Furthermore, managing blood sugar levels with rapid-acting insulin leads to better muscle recovery post-exercise, allowing for more frequent training sessions. Despite its therapeutic use, it is essential to monitor glucose levels diligently, especially in competitive settings, as fluctuations can lead to both hypoglycemic and hyperglycemic episodes. Research suggests that athletes who effectively integrate Apidra into their training regimen often achieve better results in strength and endurance competitions, making it an invaluable asset for serious competitors.
While Apidra is generally safe for individuals with diabetes, some precautions must be taken. Common side effects may include hypoglycemia, injection site reactions, and, in rare cases, allergic reactions. It is imperative that users are educated about recognizing signs of low blood sugar, as these can occur acutely during high-intensity training. Contraindications include individuals with hypersensitivity to insulin glulisine or any ingredients in the formulation.
To ensure safe and effective use of Apidra, athletes should follow these recommendations:
By adhering to these guidelines, athletes can maximize the benefits of Apidra Solostar Ready Pen, achieving optimal performance while managing their condition effectively.
| Active substance | Insulin Glulisine |
|---|---|
| Water Retention | Can cause modest water retention |
| Hepatotoxicity | No hepatotoxic effects known |
| Lab Test | Blood insulin levels, C-peptide test |
| Also known as | Exogenous insulin |
| Blood pressure | Can indirectly affect blood pressure by altering blood glucose levels |
| Trade name | Humulin, Novolin, Lantus, among others |
| Storage conditions | Must be kept refrigerated (2-8 degrees Celsius), avoid freezing |
| Chemical name | Insulin |
| Formula | C257H383N65O77S6 (for human insulin) |
| Substance class | Hormone, peptide |
| Main action | Lowers blood glucose levels |
| Half-life | Varies by type (Rapid-acting: 2-4 hours, Short-acting: 3-6 hours, Intermediate-acting: 12-18 hours, Long-acting: 20-24 hours) |
| Dosage (medical) | Depends on the patient's insulin sensitivity, carbohydrate intake, and blood glucose level, typically ranges from 0.5 to 1 unit/kg per day |
| Dosage (sports) | Not recommended for non-medical use |
| Effects | Decreases blood glucose, increases cellular glucose uptake, promotes glycogen synthesis |
| Side effects | Hypoglycemia, weight gain, insulin resistance, allergic reactions |
| Use in sports | Misused for anabolic purposes |
| Manufacturer | Sanofi |
| Packing | 1 pack (5 pens x 3ml (100 iu/ml)) |
€118.00
Reviews
There are no reviews yet.